Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Phase: N/A Priority: Normal
NCT ID: NCT05524545 Org: User:
Start: 11/02/22 End: 08/29/25 Due: 08/29/26

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Phase: N/A Priority: Normal
NCT ID: NCT04417517 Org: User:
Start: 10/02/20 End: 06/30/25 Due: 06/30/26

ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT07007559 Org: User:
Start: 04/28/25 End: 12/31/27 Due: 12/31/28

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Phase: N/A Priority: Normal
NCT ID: NCT03013218 Org: User:
Start: 02/03/17 End: 12/01/24 Due: 12/01/25

Evorpacept (ALX148) in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Phase: N/A Priority: Normal
NCT ID: NCT04675333 Org: User:
Start: 05/10/21 End: 12/31/25 Due: 12/31/26

Evorpacept (ALX148) in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Phase: N/A Priority: Normal
NCT ID: NCT04675294 Org: User:
Start: 04/02/21 End: 12/31/25 Due: 12/31/26

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Phase: N/A Priority: Normal
NCT ID: NCT04755244 Org: User:
Start: 05/05/21 End: 08/16/23 Due: 08/16/24

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Phase: N/A Priority: Normal
NCT ID: NCT05002127 Org: User:
Start: 01/15/22 End: 08/31/28 Due: 08/31/29